Perspectives
From 67% to 97%: That’s a big improvement
Point-of-sale edit upped % of Rx with <7 days supply
February 9, 2020A point-of-sale edit helped decrease large opioid supplies for new users, with a 30 percent increase in prescriptions of less than seven days supply
Evidence shows that a three-day opioid prescription is enough most of the time. The Centers for Disease Control (2016) provided these guidelines, and many states have passed laws that support them. These guidelines have worked their way into doctors’ prescribing habits, but for many, it’s a slow process. This study demonstrates how benefit design can have an immediate impact on prescribing behavior. This Blue Plan implemented a point-of-sale edit to limit new opioid prescriptions to less than seven days supply. This plan’s compliance rate jumped from 67 percent to 97 percent.
Related news
Perspectives
April 24, 2024
Prime/MRx resident wins AMCP Foundation Best Poster Award
Ai Quynh Nguyen, PharmD, was recently recognized for her research on opioid-prescribing patterns and outcomes
Perspectives
April 23, 2024
Expert Clinical Network Insights: April 2024
A look into our Expert Clinical Network (ECN) – part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance
Perspectives
April 23, 2024
April Fraud Focus – How to prioritize drug safety at home
While ensuring drug safety is often considered the responsibility of pharmaceutical industry players,…